Search
Trimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalTranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent. ...
Dinoprost tromethamine
go.drugbank.com/drugs/DB01160ApprovedVet approvedWithdrawnThe tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol...
Calcium threonate
go.drugbank.com/drugs/DB11168ApprovedWithdrawnCalcium threonate is a calcium salt of threnoic acid and a novel drug developed for the treatment of osteoporosis and as a calcium supplement . It is found in dietary supplements as a source of L-threonate used in the treatment of calciu...
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...
Categories: Somatostatin Receptor AgonistsAT9283
go.drugbank.com/drugs/DB05169InvestigationalAT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Carbamide peroxide
go.drugbank.com/drugs/DB11129ApprovedInvestigationalIt may also alter enamel surface morphology via enamel mineral loss and surface roughening [A32336].
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalIt was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: Programmed Death Receptor-1 Blocking AntibodyEladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationalapproval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter catabolism via
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have
Categories: Adrenergic alpha-1 Receptor Antagonists